Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $114
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has maintained an 'Outperform' rating on Haemonetics (NYSE:HAE) and raised the price target from $111 to $114.
August 09, 2023 | 2:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Haemonetics' stock rating has been maintained as 'Outperform' by Barrington Research, with a raised price target from $111 to $114.
The 'Outperform' rating indicates that Barrington Research expects Haemonetics to do better than the market average. The raised price target from $111 to $114 suggests that the analyst sees potential for the stock's price to increase. This could potentially lead to a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100